Genomic Test may Predict Aggressive Disease in Men Newly Diagnosed with Prostate Cancer
After a biopsy comes back positive for prostate cancer, patients and their doctors are often left with a choice between taking a watch-and-wait approach, known as active surveillance, or proceeding with surgery or radiation.
And identifying which patients will benefit from more immediate and aggressive treatment isn't always clear.
Between February 2015 and October 2019, 855 patients participating in the state Michigan Urological Surgery Improvement Collaborative registry underwent testing with the Decipher Biopsy test after being diagnosed with prostate cancer — one of the first real- world, observational studies of a commercially available genomic test designed to aid in decision-making after an initial diagnosis.
The research team found the data supported the clinical utility of the Decipher Biopsy test, according to findings published in Prostate Cancer and Prostatic Diseases.
The analysis found men with a high Decipher score who were placed on active surveillance had a shorter time before active treatment was needed, Vince said. And for those who underwent surgery to remove the prostate gland, high scores were associated with shorter time until their prostate-specific antigen (PSA) levels went up again or when they were put on anti-androgen therapy..